COVID-19 Antiviral Treatments: Insights from the ACTT-1 Study

November 26, 2024 Catherine Williams - Chief Editor Health

Addresses

National Institute of Allergy and Infectious Diseases, Bethesda.

Keywords

  • Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members
  • Humans
  • Alanine
  • RNA
  • Viral
  • Adenosine Monophosphate
  • Viral Antigens
  • Antiviral Agents
  • Treatment Outcome
  • Viral Load
  • Adult
  • Aged
  • Middle Aged
  • Female
  • Male
  • Biomarkers
  • COVID-19
  • SARS-CoV-2
  • Coronavirus Nucleocapsid Proteins
  • COVID-19 Drug Treatment